In October 2025, Protalix BioTherapeutics, Inc. (NYSE:PLX) announced that the Committee for Medicinal Products for Human Use (CHMP) issued a negative opinion regarding Chiesi’s request for four-week ...

The average one-year price target for Protalix BioTherapeutics (NYSEAM:PLX) has been revised to $11.22 / share. This is a decrease of 12.00% from the prior estimate of $12.75 dated January 11, 2026.

Ever wanted to know how engineers made their calculations before digital calculators were on every workbench? [Richard ...

After Qualcomm’s purchase of Arduino it has left many wondering what market its new Uno Q board is trying to target. Taking the ongoing RAM-pocalypse as inspiration, [Bringus Studios] made a tongue-in ...

Protalix BioTherapeutics, Inc., a biopharmaceutical company, engages in the development, production, and commercialization of recombinant therapeutic proteins based on the ProCellEx plant cell-based ...

) has been revised to $11.22 / share. This is a decrease of 12.00% from the prior estimate of $12.75 dated January 11, 2026. The price target is an average of many targets provided by analysts. The ...

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings.

The silver futures market entered 2026 in an extraordinary state, marked by historic price levels, extreme volatility, and shifting market structure. Silver futures recently surged to record nominal ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations for ...

Around 30,000 paralysis cases are reported each year worldwide from a rare neurological condition often associated with foodborne bacteria, sometimes linked to poultry products, highlighting how ...

Futures trading involves a substantial risk of loss and may not be suitable for all investors. Therefore, carefully consider whether such trading is suitable for you in light of your financial ...